Highest-materiality recent filing
Amphastar Q2 2026 revenue up 5.4% YoY to $183.9M; adjusted EPS $0.91
Net revenues of $183.9M for Q2 2026, up from $174.4M in Q2 2025.
Amphastar appoints Anthony Pierce to board, expands to 11 directors
Board increased from 10 to 11 directors; Anthony Pierce appointed as Class III director effective July 9, 2026.
Amphastar subsidiary IMS receives FDA warning letter for CGMP violations at South El Monte facility
Warning letter dated July 2, 2026, follows December 2025 FDA inspection of IMS's South El Monte, CA facility.
Amphastar shareholders elect three directors, ratify EY, approve say-on-pay
All three Class I nominees elected: Gaugh 35.2M for, Peters 23.6M for, Liawatidewi 23.2M for.
Amphastar Q1 2026 GAAP net income drops 75% to $6.4M; adjusted EPS falls to $0.42
Net revenues flat at $171.2M vs $170.5M YoY.
Amphastar Board authorizes $50M increase to share buyback program
Board authorized $50M increase to buyback program on March 12, 2026.
Amphastar enters supply agreement with related party Letop, amends contract with Hanxin
Supply agreement with Nanjing Letop (Henry Zhang, son of CEO); no minimum purchase, 5-year term.
Amphastar enters employment agreements with two executives; base salaries $525,800 and $590,000
Jacob Liawatidewi (EVP of Corp Admin) base salary $525,800, target bonus 55%.
Amphastar Q4 revenue $183.1M, down 1.8% YoY; GAAP EPS $0.51 vs $0.74
Full year 2025 net revenue $719.9M, down 1.6% YoY from $732.0M.
Amphastar Licenses Synthetic Corticotropin (AMP-110) from Hanxin in Exclusive US/Canada Deal
Amphastar gained exclusive rights to develop and commercialize AMP-110 (synthetic ACTH) in the US and Canada from Nanjing Hanxin.
Amphastar Q3 net income drops 57% YoY to $17.4M; adjusted EPS $0.93 vs $0.96
Net revenues of $191.8M, flat YoY vs $191.2M.
Amphastar enters exclusive BAQSIMI distribution deal for Greater China with related party
Exclusive distributor Chengong will market BAQSIMI in Mainland China, Taiwan, Hong Kong, Macau.
Amphastar enters $2.8M R&D agreement with related-party Hanxin for AMP-107 cell banks
Agreement with Nanjing Hanxin to develop Recombinant Peptide Research Cell Banks (RCBs) for product candidate AMP-107.
Amphastar licenses three novel peptides from Anji for up to $453M total
Exclusive license for three proprietary peptides targeting oncology and ophthalmology in U.S. and Canada.
Amphastar Q2 2025 revenue $174.4M, GAAP EPS $0.64; BAQSIMI sales up 21%
Net revenues $174.4M vs $182.4M YoY; GAAP net income $31.0M ($0.64 diluted EPS).
Amphastar appoints David Gaugh as Class I director; board size increased to 11
Board increased authorized directors from 10 to 11 and appointed David Gaugh effective July 18, 2025.
Elected three Class III directors: Jack Y. Zhang, Richard Prins, Diane G. Gerst (each with majority support).
Amphastar Q1 2025 GAAP net income $25.3M ($0.51 EPS); adjusted EPS $0.74
Net revenues $170.5M, down from $171.8M in Q1 2024.
Amphastar Q4 net revenue $186.5M, adj EPS $0.92; FY $732M, adj EPS $3.86
Q4 net revenue $186.5M, up 4.7% YoY; GAAP net income $38.0M ($0.74 per share).
Amphastar Q3 2024 revenue up 5.9% to $191.2M; adjusted EPS down to $0.96
Net revenues $191.2M vs $180.6M in Q3 2023, up 5.9%.
Armstrong (Amphastar subsidiary) appoints Genreach as exclusive distributor for Primatene MIST in Mainland China, Taiwan, Hong Kong, Macau; 10-year term.
Amphastar Q2 revenue $182.4M, adjusted EPS $0.94; both up ~25-45% YoY
Net revenues $182.4M (Q2) vs $145.7M YoY; six-month $354.2M vs $285.7M.
Amphastar board authorizes $50M increase to share buyback program to offset dilution
$50M increase to buyback program authorized June 3, 2024; program continues indefinitely.
Amphastar Q1 2024 net revenue $171.8M, GAAP EPS $0.81, adjusted EPS $1.04
Net revenues of $171.8M vs $140.0M in Q1 2023, up 23% YoY.
Amphastar Q4 net revenue $178.1M, GAAP EPS $0.68; FY revenue $644.4M
Q4 2023 net revenue $178.1M (+32% YoY); GAAP net income $36.2M ($0.68 EPS).
Amphastar Q3 revenue up 50% to $180.6M; GAAP EPS $0.91, adj. $1.15
Net revenues of $180.6M for Q3 2023, up from $120.1M in Q3 2022 (50% increase).
Amphastar issues $345M 2% convertible senior notes due 2029; repays $200M term loan, buys $50M stock
$345M aggregate principal (incl. $45M greenshoe exercised) of 2.00% convertible senior notes due 2029, sold via Rule 144A.
Amphastar files BAQSIMI financials: 2022 revenue $139.3M, revenue less direct expenses $59.8M
BAQSIMI 2022 revenue $139.3M (up 23% YoY from $113.2M); revenue less direct expenses $59.8M vs -$2.3M in 2021.
Amphastar Q2 2023 revenue $145.7M, GAAP EPS $0.49, adj. EPS $0.65
Net revenues $145.7M for Q2 2023, up 18% from $123.5M in Q2 2022.
Amphastar completes $500M acquisition of BAQSIMI from Lilly; funds with $500M term loan
Paid $500M cash at closing; also owes $125M guaranteed payment in one year plus up to $450M contingent milestones.
Floyd F. Petersen, Jacob Liawatidewi, and William J. Peters elected as Class I directors to serve until 2026.
Amphastar Q1 revenues $140M (+16% YoY); GAAP EPS $0.50, adj. EPS $0.62
Net revenues $140.0M vs $120.4M YoY; GAAP net income $26.0M ($0.50 diluted EPS).
Amphastar to buy Lilly's BAQSIMI for $500M cash, $125M guarantee, up to $450M milestones
Purchase price: $500M cash at closing, $125M guaranteed payment at 1-year anniversary, plus up to $450M in sales-based milestones.
Amphastar enters $0.5M amendment with related party Hanxin for insulin R&D scale-up
Amendment to Contract Research Agreement dated July 5, 2022 with Nanjing Hanxin Pharmaceutical Technology Co., Ltd.
Amphastar Q4 revenue $135M (+11.7% YoY); GAAP EPS $0.66; full-year revenue $499M (+14.0% YoY)
Q4 2022 net revenue $135.0M vs $120.9M YoY; GAAP net income $33.9M ($0.66 diluted EPS) vs $19.8M ($0.39).
Board approved Amended and Restated Bylaws on Feb 23, 2023.
Amphastar subsidiary enters up to $1.5M supply deal with related party Letop Biotech
ANP subsidiary signed 3-year supply agreement with Nanjing Letop Biotechnology for chemical intermediates.
Amphastar Q3 revenue up 7% to $120.1M; GAAP EPS falls to $0.30 from $0.59 YoY
Net revenues $120.1M for Q3 2022, up from $112.2M in Q3 2021 (7% growth).
Amphastar expands board to 10, appoints CFO Peters and EVP Liawatidewi as directors
Board size increased from 8 to 10, effective August 4, 2022.
Amphastar Q2 2022 net revenue up 21.5% YoY to $123.5M; GAAP EPS $0.33
Net revenues $123.5M for Q2 2022, up from $101.7M in Q2 2021 (21.5% increase).
Amphastar enters $2.2M R&D agreement with related party Hanxin for insulin cell banks
Agreement with Nanjing Hanxin to develop Recombinant Human Insulin Research Cell Banks (RCBs) and provide exclusive worldwide license.
Elected directors Jack Zhang, Richard Prins, Diane Gerst; Zhang received 31,356,354 for, Prins 28,273,064, Gerst 25,594,041.
Amphastar Q1 2022 revenue $120.4M (+17% YoY); GAAP EPS $0.47 vs $0.10
Net revenues $120.4M for Q1 2022, up from $103.0M in Q1 2021 (+17% YoY).
Amphastar subsidiary enters contract manufacturing deal with related party Hanxin for Chinese market
ANP will manufacture APIs and finished products on cost-plus basis for Hanxin, which will file for Chinese marketing authorizations.
Amphastar Q4 revenue $120.9M, GAAP EPS $0.39; full-year net income $62.1M
Q4 net revenues $120.9M vs $95.9M in Q4 2020, up 26%; GAAP net income $19.8M vs loss of $6.3M.
Amphastar Q3 net revenues up 34% YoY to $112.2M; GAAP EPS $0.59 vs $0.08
Net revenues $112.2M (Q3 2021), up 34% from $83.4M in Q3 2020.
Amphastar director David Maris resigns effective immediately; no disagreement with company
David Maris resigned from the Board on August 19, 2021, effective immediately.
Amphastar to acquire remaining ~15% of Nanjing subsidiary for $22.5M cash
Signed SPA for ~15% stake in Amphastar Nanjing Pharmaceuticals (ANP) from QQ for ~$22.5M.
Director Richard Koo to retire from Amphastar Board effective Sept 30, 2021
Richard Koo announced retirement from Board effective September 30, 2021; not due to any disagreement.
Amphastar refinances existing debt with new $140M credit facility from Capital One, East West
New $140M credit facility comprises $70M term loan and $70M revolving line, both five-year maturity.
appointed each of William J. Peters, the Company’s Chief Financial Officer, Executive Vice President of Finance, and Treasurer, and Jacob Liawatidewi, the Company’s Executive Vice President of Corporate Administration Center, and Sales and Marketing (together with Mr. Peters, the “New Directors”), to serve as Class I directors
appointed each of William J. Peters, the Company’s Chief Financial Officer, Executive Vice President of Finance, and Treasurer, and Jacob Liawatidewi, the Company’s Executive Vice President of Corporate Administration Center, and Sales and Marketing (together with Mr. Peters, the “New Directors”), to serve as Class I directors
On August 19, 2021, David Maris tendered his resignation to the Board of Directors (the “ Board ”) of Amphastar Pharmaceuticals, Inc. (the “ Company ”) effective immediately.
On August 5, 2021, Richard Koo announced his retirement from the Board of Directors (the “Board”) of Amphastar Pharmaceuticals, Inc. (the “Company”) effective as of September 30, 2021.
Max materiality 0.85 · Median 0.60 · Most common event earnings